Kardio-metabolische Charakterisierung von Patienten mit Typ 2 ...

53. Evidenzbasierte Diabetes-Leitlinien DDG: „Management der Hypertonie beim
Patienten mit Diabetes mellitus”, 2000.
54. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR,
Cole TG, Pfeffer MA, Braunwald E: Cardiovascular events and their reduction with
pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with
average cholesterol levels: subgroup analyses in the cholesterol and recurrent events
(CARE) trial. The Care Investigators. Circulation 1998; 98: 2513-2519.
55. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ,
Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators:
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in
the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised
placebo-controlled trial. Lancet 2004; 364: 685-696.
56. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent
C: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14
randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117–125.
57. Dierkx RI, van de Hoek W, Hoekstra JB, Erkelens DW: Smoking and diabetes
mellitus. Neth J Med 1996; 48:150-162
58. Meinertz T und Heitzer T: Primary and secondary prevention of coronary heart
disease: smoking. Z Kardiol 2002; 91: Suppl 2, 3-11.
45